Every Cure

07/21/2026

We're excited to share that one of Every Cure's programs has reached a huge milestone.

Lenalidomide/dexamethasone is now a preferred treatment option in the NCCN Guidelines for Rosai Dorfman disease (RDD).

This milestone was made possible through a collaboration between Dr. Luke Chen and the Every Cure team. Using our AI powered platform, we systematically evaluated nearly 3,000 FDA approved drugs and identified lenalidomide as one of the most promising repurposing candidates.

Together with Dr. Chen's clinical expertise and research, we helped strengthen the evidence supporting this treatment, work that ultimately contributed to its inclusion as a preferred option in the NCCN Guidelines.

But getting a treatment into the guidelines is only part of the journey.

Now we need your help to make sure this information reaches the clinicians and patients who can benefit.

Here's how you can help:
• Share this post to your story.
• Send it to a hematologist or oncologist you know.
• Follow Every Cure as we continue working to identify overlooked treatments and help them reach patients around the world.

This is exactly why Every Cure exists. Not just to discover repurposed treatments, but to ensure those discoveries make a real difference in patients' lives.

Learn more by reading our press release by clicking the link below:
everycure.org/rdd

07/14/2026

*Had to follow this IG trend. No Netflix documentary is actually in the works*

Of the world’s 18,000 recognized diseases, only about 4,000 have approved treatments.

We know many of these diseases could be treated with many of the existing FDA-approved drugs.

But systemic barriers prevent this from happening. It’s just not profitable to pursue a new use for an existing drug, especially for rare diseases and the 80% of drugs that are already generic and inexpensive.

Until recently, it has also been logistically impossible to scan across the world’s knowledge of all drugs and all diseases to find matches.

So the system focuses on new drugs for profitable diseases, and no one has taken responsibility for systematically uncovering these hidden treatments. Until now.

is addressing each of the system’s barriers to find the best matches to save and improve lives.

05/27/2026

“My mom was covered in painful lesions from head to toe. Doctors kept walking into the room saying the same thing: ‘We’ve never seen this before.’

At first, they thought it might be cancer. She had lost a dangerous amount of weight, her body was overwhelmed with inflammation, and nobody could explain why she kept getting worse. My family went from hospital to hospital searching for answers while my mom’s health slowly deteriorated in front of us.

Eventually, after months of testing, biopsies, and uncertainty, doctors diagnosed her with a rare disease called Rosai-Dorfman Disease, or RDD. We had never heard of it before. And honestly, most doctors hadn’t either.

For years, we kept hearing different opinions from specialists across dermatology, infectious disease, and hematology, but nobody really seemed to know what to do next. Then we met Dr. Luke Chen.

Right away, we could tell he understood this disease differently. He told us about a treatment called lenalidomide and even helped my mom get access to it through compassionate care. Slowly, we started seeing changes. The lesions covering her body began healing. Her strength started coming back. She was finally getting pieces of her life back.

Today, she still deals with fatigue and carries scars from everything she’s been through, but she’s walking on her own again, grocery shopping, cooking, and doing the things she loves.
RDD changed our lives completely. But it also taught us how important it is to find doctors who truly understand rare diseases—and how life changing the right treatment can be.”

04/24/2026

Can Every Cure prioritize one disease over another and accelerate a cure on demand? It’s one of the most common questions we get.

The reality is that Every Cure is built to look across all 18,000 diseases at once, systematically scoring thousands of drugs against each one. We are not yet in a position to focus exclusively on a single condition by request. Instead, we work through this massive landscape methodically, reviewing more than 1,000 opportunities every month to identify the most promising matches between existing drugs and diseases.

What is powerful is the scale of this approach. There is a real chance we are already evaluating a potential treatment for the disease you care about.

In many cases, the answer is not starting from scratch. It is uncovering something that may already exist and accelerating it forward with the right data, resources, and collaboration.

This clip was recorded at the Peter Diamandis Abundance Summit. So grateful to be part of a community pushing the boundaries of what’s possible in healthcare and beyond.

04/15/2026